MX2022004678A - Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer. - Google Patents

Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.

Info

Publication number
MX2022004678A
MX2022004678A MX2022004678A MX2022004678A MX2022004678A MX 2022004678 A MX2022004678 A MX 2022004678A MX 2022004678 A MX2022004678 A MX 2022004678A MX 2022004678 A MX2022004678 A MX 2022004678A MX 2022004678 A MX2022004678 A MX 2022004678A
Authority
MX
Mexico
Prior art keywords
disease
beta
treating alzheimer
amyloid antibody
antibody
Prior art date
Application number
MX2022004678A
Other languages
English (en)
Spanish (es)
Inventor
Thierry Bussiere
Roger Nitsch
Haeberlein Samantha Budd
Ying Tian
Laura Nisenbaum
Raj Rajagovindan
Gersham Dent
John Beaver
Edward Plowey
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MX2022004678A publication Critical patent/MX2022004678A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2022004678A 2019-10-22 2020-10-21 Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer. MX2022004678A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962924633P 2019-10-22 2019-10-22
PCT/US2020/056676 WO2021081101A1 (en) 2019-10-22 2020-10-21 Anti-beta-amyloid antibody for treating alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2022004678A true MX2022004678A (es) 2022-08-15

Family

ID=73344157

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004678A MX2022004678A (es) 2019-10-22 2020-10-21 Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.

Country Status (13)

Country Link
US (1) US20220372123A1 (cg-RX-API-DMAC10.html)
EP (1) EP4048695A1 (cg-RX-API-DMAC10.html)
JP (2) JP2022553329A (cg-RX-API-DMAC10.html)
KR (1) KR20220084095A (cg-RX-API-DMAC10.html)
CN (1) CN114599393A (cg-RX-API-DMAC10.html)
AU (1) AU2020371612A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022007595A2 (cg-RX-API-DMAC10.html)
CA (1) CA3158513A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022004902A2 (cg-RX-API-DMAC10.html)
IL (1) IL292363A (cg-RX-API-DMAC10.html)
JO (1) JOP20220092A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022004678A (cg-RX-API-DMAC10.html)
WO (1) WO2021081101A1 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
EP3746476A1 (en) 2018-01-31 2020-12-09 Alector LLC Anti-ms4a4a antibodies and methods of use thereof
EP3746484A4 (en) 2018-01-31 2021-11-17 Alector LLC ANTI-MS4A6A ANTIBODY AND METHOD OF USING THEREOF
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
TW202300517A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2023081194A2 (en) * 2021-11-03 2023-05-11 Biogen Ma Inc. Methods for treating alzheimer's disease
KR20240142535A (ko) * 2022-02-02 2024-09-30 에자이 알앤드디 매니지먼트 가부시키가이샤 P-tau181 수준을 사용한 치료 방법
WO2024086796A1 (en) * 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
EP4608432A4 (en) * 2022-10-25 2026-08-12 Inst For Basic Science Ibs EXTRACTION METHODS TO ENABLE CEREBRAL-SPINAL FLUID DRAINAGE
EP4455161A1 (en) 2023-04-24 2024-10-30 ONO Pharmaceutical Co., Ltd. Human-derived anti-collapsin response mediator protein 2 (crmp2) antibodies
WO2025059487A2 (en) 2023-09-15 2025-03-20 Othair Prothena Limited Cell penetrating agents and uses thereof
WO2025117721A1 (en) * 2023-11-27 2025-06-05 Massachusetts Institute Of Technology Reconstituted lipoprotein particles to rescue lipid defects in the alzheimer's brain

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033325T2 (en) 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
US9040045B2 (en) * 2007-05-14 2015-05-26 Medtronic, Inc. Methods and device to neutralize soluble toxic agents in the brain
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9221900B2 (en) * 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
EP3275461A1 (en) * 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
EP2928494A4 (en) * 2012-12-07 2016-11-02 Biogen Internat Neuroscience Gmbh METHOD FOR REDUCING AMYLOIDER PLAQUE OF BRAIN WITH ANTI-ASS ANTIBODIES
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
MX2018015022A (es) * 2016-06-07 2019-08-14 Biogen Int Neuroscience Gmbh Métodos para el tratamiento de la enfermedad de alzheimer.

Also Published As

Publication number Publication date
CO2022004902A2 (es) 2022-07-08
JP2022553329A (ja) 2022-12-22
EP4048695A1 (en) 2022-08-31
CN114599393A (zh) 2022-06-07
BR112022007595A2 (pt) 2022-08-23
US20220372123A1 (en) 2022-11-24
AU2020371612A1 (en) 2022-05-19
CA3158513A1 (en) 2021-04-29
IL292363A (en) 2022-06-01
JOP20220092A1 (ar) 2023-01-30
KR20220084095A (ko) 2022-06-21
WO2021081101A1 (en) 2021-04-29
JP2026012271A (ja) 2026-01-23

Similar Documents

Publication Publication Date Title
CO2022004902A2 (es) Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer
CO2019011349A2 (es) Anticuerpos anti-péptido beta amiloide n3pglu y sus usos
ZA202107358B (en) Method for treating alzheimer's disease
CL2021003132A1 (es) Anticuerpos que se unen a cd3 (divisional de solicitud n° 202101506)
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
CO2021009693A2 (es) Proteínas de unión a antígeno del receptor gamma anti-il2
MX2018015022A (es) Métodos para el tratamiento de la enfermedad de alzheimer.
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
ECSP21052193A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
MX394462B (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS.
MX2020005651A (es) Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
EA201892190A1 (ru) Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
MX2024006689A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
BR112021011729A2 (pt) Tubulisinas e conjugados de proteína-tubulisina
CL2021001389A1 (es) Formulaciones en cápsula
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
AR119159A1 (es) Tratamientos de angioedema
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2024012437A (es) Inhibidores de oxadiazol hdac6 y usos de estos
BR112022002236A2 (pt) Composições, composições farmacêuticas e uso das mesmas para tratar câncer, bem como formulações que compreendem as mesmas
CO2018013828A2 (es) Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato